tubulin inhibitor compound

AMRI,Chai Therapeutics Have Signed a Licensing Deal Developing Tubulin Inhibitor Compound
Feb 18, 2013
Albany Molecular Research (AMRI) and Chai Therapeutics, an affiliate of Bessor Pharma, have signed a licensing deal to develop tubulin inhibitor compound, ALB 109564(a), for cancer treatment. AMRI's ALB 109564(a) is a novel analog ...

Tags: AMRI, Chai Therapeutics, tubulin inhibitor compound